Kindlin-2 modulates MafA and β-catenin expression to regulate β-cell function and mass in mice

Area of Science:

• Endocrinology
• Cell Biology
• Molecular Biology

Background:

• Diabetes mellitus is characterized by beta-cell dysfunction and reduced beta-cell mass.
• The molecular mechanisms regulating beta-cell function and mass are not fully understood.

Purpose of the Study:

• To investigate the role of Kindlin-2 in beta-cell function and mass.
• To elucidate the molecular mechanisms by which Kindlin-2 regulates beta-cells.
• To determine if Kindlin-2 is a potential therapeutic target for diabetes.

Main Methods:

• Deletion of Kindlin-2 expression in beta-cells.
• In vitro studies using primary human and mouse islets.
• In vivo studies in mouse models.
• Analysis of insulin secretion, calcium release, cell proliferation, and cell mass.
• Genetic manipulation of beta-catenin signaling.

Main Results:

• Kindlin-2 deletion in beta-cells leads to severe diabetes-like phenotypes.
• Kindlin-2 stabilizes MafA, activating insulin expression.
• Kindlin-2 loss impairs insulin secretion by reducing calcium release.
• Kindlin-2 loss activates GSK-3β, downregulates β-catenin, reducing beta-cell proliferation and mass.
• Kindlin-2 loss alters islet cell composition during development.
• Genetic activation of β-catenin rescues diabetes-like phenotypes.
• Inducible deletion of Kindlin-2 in adult mice causes diabetes.

Conclusions:

• Kindlin-2 plays a critical role in maintaining beta-cell function and mass.
• Kindlin-2 regulates insulin expression and secretion through MafA stabilization.
• Kindlin-2 impacts beta-cell proliferation and survival via the β-catenin pathway.
• Kindlin-2 is a potential therapeutic target for diabetes mellitus.